 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Opdivo (nivolumab) / BMS, ONO-7807 / BMS, Ono Pharma
Trial completion date: An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Apr 4, 2024
P1/2, N=92, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Dec 2024 --> Apr 2025
- || Opdivo (nivolumab) / BMS, ONO-7807 / BMS, Ono Pharma
Trial completion date, Trial primary completion date: An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Sep 7, 2023
P1/2, N=92, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Dec 2024 --> Apr 2025 Trial completion date: Mar 2023 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Dec 2024
- ||| Opdivo (nivolumab) / BMS, ONO-7807 / BMS, Ono Pharma
Enrollment closed, Enrollment change: An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Feb 14, 2022
P1/2, N=92, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Mar 2023 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Dec 2024 Recruiting --> Active, not recruiting | N=248 --> 92
- || Opdivo (nivolumab) / BMS, ONO-7807 / BMS, Ono Pharma
Trial completion date, Trial primary completion date: An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Jan 11, 2022
P1/2, N=248, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=248 --> 92 Trial completion date: Jul 2024 --> Mar 2023 | Trial primary completion date: Jul 2024 --> Mar 2023
- ||| Opdivo (nivolumab) / BMS, ONO-7807 / BMS, Ono Pharma
Enrollment change, Trial completion date, Trial primary completion date: An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - May 12, 2021
P1/2, N=248, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jul 2024 --> Mar 2023 | Trial primary completion date: Jul 2024 --> Mar 2023 N=368 --> 248 | Trial completion date: Mar 2025 --> Jul 2024 | Trial primary completion date: Mar 2025 --> Jul 2024
- || Opdivo (nivolumab) / BMS, ONO-7807 / BMS, Ono Pharma
Trial completion date, Trial primary completion date: An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Nov 25, 2020
P1/2, N=368, Recruiting, Sponsor: Bristol-Myers Squibb
N=368 --> 248 | Trial completion date: Mar 2025 --> Jul 2024 | Trial primary completion date: Mar 2025 --> Jul 2024 Trial completion date: Jul 2023 --> Mar 2025 | Trial primary completion date: Jul 2023 --> Mar 2025
- | Opdivo (nivolumab) / BMS, ONO-7807 / BMS, Ono Pharma
New P1/2 trial: An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Aug 24, 2018
P1/2, N=308, Recruiting, Sponsor: Bristol-Myers Squibb
- |||| Opdivo (nivolumab) / BMS, ONO-7807 / BMS, Ono Pharma
Enrollment open: An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Mar 19, 2018
P1/2, N=260, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Jul 2023 --> Mar 2025 | Trial primary completion date: Jul 2023 --> Mar 2025 Not yet recruiting --> Recruiting
- ||||| Opdivo (nivolumab) / BMS, ONO-7807 / BMS, Ono Pharma
New P1/2 trial: An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (clinicaltrials.gov) - Feb 25, 2018
P1/2, N=260, Not yet recruiting, Sponsor: Bristol-Myers Squibb